Wei Chen, Paranjpe Ishan, Sharma Pranav, Milligan Michael, Lam Miranda, Heidenreich Paul A, Kalwani Neil, Schulman Kevin, Sandhu Alexander
Department of Medicine Stanford University School of Medicine Stanford CA.
Drexel University College of Medicine Philadelphia PA.
J Am Heart Assoc. 2024 Feb 20;13(4):e031982. doi: 10.1161/JAHA.123.031982. Epub 2024 Feb 16.
Little is known about hospital pricing for coronary artery bypass grafting (CABG). Using new price transparency data, we assessed variation in CABG prices across US hospitals and the association between higher prices and hospital characteristics, including quality of care.
Prices for diagnosis related group code 236 were obtained from the Turquoise database and linked by Medicare Facility ID to publicly available hospital characteristics. Univariate and multivariable analyses were performed to assess factors predictive of higher prices. Across 544 hospitals, median commercial and self-pay rates were 2.01 and 2.64 times the Medicare rate ($57 240 and $75 047, respectively, versus $28 398). Within hospitals, the 90th percentile insurer-negotiated price was 1.83 times the 10th percentile price. Across hospitals, the 90th percentile commercial rate was 2.91 times the 10th percentile hospital rate. Regional median hospital prices ranged from $35 624 in the East South Central to $84 080 in the Pacific. In univariate analysis, higher inpatient revenue, greater annual discharges, and major teaching status were significantly associated with higher prices. In multivariable analysis, major teaching and investor-owned status were associated with significantly higher prices (+$8653 and +$12 200, respectively). CABG prices were not related to death, readmissions, patient ratings, or overall Centers for Medicare and Medicaid Services hospital rating.
There is significant variation in CABG pricing, with certain characteristics associated with higher rates, including major teaching status and investor ownership. Notably, higher CABG prices were not associated with better-quality care, suggesting a need for further investigation into drivers of pricing variation and the implications for health care spending and access.
关于冠状动脉搭桥术(CABG)的医院定价知之甚少。利用新的价格透明度数据,我们评估了美国各医院CABG价格的差异以及较高价格与医院特征(包括医疗质量)之间的关联。
从绿松石数据库获取诊断相关组代码236的价格,并通过医疗保险机构ID与公开可用的医院特征相链接。进行单变量和多变量分析以评估预测较高价格的因素。在544家医院中,商业支付和自付费用的中位数分别是医疗保险费率的2.01倍和2.64倍(分别为57240美元和75047美元,而医疗保险费率为28398美元)。在医院内部,第90百分位数的保险公司协商价格是第10百分位数价格的1.83倍。在不同医院之间,第90百分位数的商业费率是第10百分位数医院费率的2.91倍。地区医院价格中位数从东中南部的35624美元到太平洋地区的84080美元不等。在单变量分析中,较高的住院收入、更多的年度出院量和主要教学地位与较高价格显著相关。在多变量分析中,主要教学地位和投资者所有状态与显著较高的价格相关(分别增加8653美元和12200美元)。CABG价格与死亡率、再入院率、患者评分或医疗保险和医疗补助服务中心的医院总体评级无关。
CABG定价存在显著差异,某些特征与较高价格相关,包括主要教学地位和投资者所有制。值得注意的是,较高的CABG价格与更好的医疗质量无关,这表明需要进一步调查价格差异的驱动因素及其对医疗保健支出和可及性的影响。